Evofem Biosciences Enters Material Agreement, Files 8-K
Ticker: EVFM · Form: 8-K · Filed: Sep 25, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: EVFM
TL;DR
EVFM inked a material deal, filed an 8-K. Details TBD.
AI Summary
Evofem Biosciences, Inc. announced on September 20, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement and sales were not provided in this summary.
Why It Matters
This filing indicates significant corporate activity, potentially involving new partnerships, financing, or strategic shifts for Evofem Biosciences.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and unregistered sales of equity, which can introduce uncertainty and potential dilution.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- September 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36754 (commission_file_number) — SEC File Number
- 20-8527075 (tax_id) — I.R.S. Employer Identification No.
- San Diego, California (location) — Principal executive offices address
- (858) 550-1900 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement?
The filing states that Evofem Biosciences, Inc. entered into a Material Definitive Agreement on September 20, 2024, but the specific terms and nature of the agreement are not detailed in the provided text.
What type of equity securities were sold unregistered?
The filing mentions unregistered sales of equity securities, but the specific type and details of these sales are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 20, 2024.
What is Evofem Biosciences, Inc.'s state of incorporation?
Evofem Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Evofem Biosciences, Inc.?
The principal executive office address is 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Filing Stats: 1,029 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-25 16:15:29
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $260,000 — ck") for an aggregate purchase price of $260,000. The powers, preferences, rights, quali
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 281KB
- ex10-2.htm (EX-10.2) — 200KB
- 0001493152-24-038113.txt ( ) — 805KB
- evfm-20240920.xsd (EX-101.SCH) — 3KB
- evfm-20240920_lab.xml (EX-101.LAB) — 33KB
- evfm-20240920_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: September 25, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer